Skip to content

Sermorelin Acetate

Emerging evidence

Sermorelin is a short GHRH fragment (1-29) that stimulates pituitary GH release. It has a short half-life, supporting pulsatile dosing. Not medical advice; consult a provider.

How Sermorelin Acetate works

Sermorelin acts at the pituitary to stimulate GH secretion. It does not extend GH half-life like CJC-1295 with DAC. Provider oversight required.

Researched benefits

  • •Pulsatile GH release pattern
  • •Shorter half-life than longer GHRH analogs
  • •Research in body composition and recovery
  • •Often combined with GHRPs like Ipamorelin

What it is studied for

  • •Growth hormone support in research
  • •Recovery and body composition when paired with GHRP
  • •Protocols seeking more natural GH pulse pattern

Reported side effects and cautions

  • •Injection-site reactions
  • •GH-related effects; monitoring recommended
  • •Not for use in active cancer or certain conditions

Dosing protocol described in the literature

Dosage
250-500mcg
Frequency
Nightly
Administration
Subcutaneous
Cycle
6-12 months

Growth hormone support

Work out the reconstitution for this dose →

Evidence rating: Emerging evidence

Some human data exists but the evidence base is limited — often small studies, narrow indications, or trials still under way.

Other peptides

BPC157TB500 (Thymosin B4 Acetate)Semaglutide (Ozempic / Wegovy)Tirzepatide (GLP-1/GIP dual agonist)CagrilintideRetatrutide + Cagrilintide (combination)

See every peptide in the library →

Educational information only. This page is not medical advice, not a prescription, and not a recommendation to use Sermorelin Acetate. Dosing figures describe what appears in published research and provider protocols — they are not instructions. Several compounds covered here are prescription medicines. Talk to a licensed healthcare provider before acting on anything you read.